Sarepta hits high on Phase I/IIa DMD readout

By Jaime De Leon | Jun 19, 2018 | 6:52 PM GMT

Sarepta Therapeutics Inc. (NASDAQ:SRPT) hit an all-time high Tuesday morning, adding $71.26 (68%) to $176.50 and pushing the company's market cap over $11 billion, after reporting preliminary data from a Phase I/IIa trial evaluating AAVrh74.MHCK7.micro-Dystrophin to treat